Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.56 |
| ▸ | TUBB | P07437 | 2/20 | 0.56 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.56 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.56 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.56 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.56 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.56 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.56 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.56 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.56 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.56 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.56 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.56 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9817994 | 1.00 | MEN1 (0.58) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL30317323 | 0.83 | NPC1 (0.62) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL11999774 | 0.83 | NPC1 (0.62) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL29779566 | 0.82 | NPC1 (0.60) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL333836 | 0.82 | NPC1 (0.60) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL6611670 | 0.82 | NPC1 (0.60) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL333837 | 0.82 | NPC1 (0.60) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL11547241 | 0.80 | TUBB4A (0.54) | MEN1NPC1RAB9AKMT2AATM | |
| SCHEMBL11547236 | 0.80 | TUBB4A (0.54) | MEN1NPC1RAB9AKMT2AATM | |
| Methyl Alcohol SCHEMBL28478479 | 0.80 | NPC1 (0.89) | MEN1NPC1RAB9AKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266015-A1 | FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS | KUMQUAT BIOSCIENCES INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2021058018-A1 | INHIBITORS OF KRAS G12C | BEIGENE, LTD. (KY) | 2021-04-01 | — | — | WO | disclosed |
| EP-3508204-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3035936-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303576-A1 | ENZYME INHIBITORS | HDAC1, HDAC4, HDAC3 | MEN1 3303/4885NPC1 1950/4885RAB9A 4776/4885 |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MEN1 2593/4885NPC1 3185/4885RAB9A 1145/4885 |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | MEN1 440/4885NPC1 1884/4885RAB9A 2457/4885 |
| US-20140155439-A1 | ENZYME INHIBITORS | HDAC4, HDAC1, HDAC3 | MEN1 3882/4885NPC1 3423/4885RAB9A 4584/4885 |
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | MEN1 346/4885NPC1 1626/4885RAB9A 924/4885 |
| US-20120149736-A1 | ENZYME INHIBITORS | HAT1, HDAC1, NAT1 | MEN1 2920/4885NPC1 1426/4885RAB9A 4822/4885 |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CDK2, MAP3K6, MAP3K2 | MEN1 3473/4885NPC1 3158/4885RAB9A 2611/4885 |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | MEN1 440/4885NPC1 1884/4885RAB9A 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.